Metastatic malignant melanoma mimicking a salivary gland basaloid neoplasm after treatment with nivolumab

Diagn Cytopathol. 2021 Sep;49(9):E370-E373. doi: 10.1002/dc.24817. Epub 2021 Jun 26.

Abstract

Malignant melanoma is a well-known diagnostic pitfall, given its propensity to metastasize to different sites and mimic various entities. In this report, we present a fine-needle aspiration biopsy (FNA) of a metastatic melanoma with basaloid features that is occurring in the preauricular/parotid area. The patient is a 17-year-old male with a history of excision of melanoma of the left temple, and was undergoing adjuvant treatment with nivolumab. The prior excision was positive for S100, HMB-45, melan-A, and tyrosinase. On follow-up, he presented with non-FDG avid left preauricular area lesions. FNA was performed, and on-site evaluation demonstrated a cellular basaloid neoplasm with focal fibrillary stroma. Immunohistochemical stains revealed that the tumor cells were positive for SOX-10, S100, MITF, and HMGA2, and were negative for HMB-45, melan-A, tyrosinase, p63, cam 5.2 and PLAG1. The positive S100, SOX-10, and MITF results and negative cam 5.2 result supported the diagnosis of melanoma. Nivolumab was then stopped, Dabrafenib/Trametinib were started, and the patient underwent excision of the nodules. Nine-months later, he developed a rib metastasis that was positive for S100, SOX-10, melan-A, and tyrosinase. This report emphasizes that melanoma involving the parotid gland region has the potential to be misdiagnosed by FNA as a salivary gland neoplasm because of overlapping cytologic features and immunophenotypes. This pitfall is avoided by careful morphologic analysis and judicious use of ancillary studies.

Keywords: FNA; basaloid; melanoma; nivolumab; parotid.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / metabolism
  • Biopsy, Fine-Needle
  • Diagnosis, Differential
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / therapeutic use
  • Male
  • Melanoma / metabolism
  • Melanoma / pathology*
  • Neoplasm Metastasis
  • Nivolumab / administration & dosage
  • Nivolumab / therapeutic use
  • Oximes / administration & dosage
  • Oximes / therapeutic use
  • Pyridones / administration & dosage
  • Pyridones / therapeutic use
  • Pyrimidinones / administration & dosage
  • Pyrimidinones / therapeutic use
  • Salivary Gland Neoplasms / metabolism
  • Salivary Gland Neoplasms / pathology*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Imidazoles
  • Oximes
  • Pyridones
  • Pyrimidinones
  • Nivolumab
  • trametinib
  • dabrafenib